Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Retained Earnings: 2010-2024

Historic Retained Earnings for Heron Therapeutics (HRTX) over the last 12 years, with Dec 2024 value amounting to -$1.9 billion.

  • Heron Therapeutics' Retained Earnings fell 0.71% to -$1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 billion, marking a year-over-year decrease of 0.71%. This contributed to the annual value of -$1.9 billion for FY2024, which is 0.71% down from last year.
  • Latest data reveals that Heron Therapeutics reported Retained Earnings of -$1.9 billion as of FY2024, which was down 0.71% from -$1.9 billion recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' Retained Earnings ranged from a high of -$1.4 billion in FY2020 and a low of -$1.9 billion during FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$1.9 billion (2023), whereas its average is -$1.9 billion.
  • Data for Heron Therapeutics' Retained Earnings shows a maximum YoY dropped of 19.50% (in 2020) over the last 5 years.
  • Over the past 5 years, Heron Therapeutics' Retained Earnings (Yearly) stood at -$1.4 billion in 2020, then decreased by 15.85% to -$1.6 billion in 2021, then dropped by 11.28% to -$1.8 billion in 2022, then fell by 6.16% to -$1.9 billion in 2023, then dropped by 0.71% to -$1.9 billion in 2024.